Marshall Wace’s Meridian Bioscience Inc VIVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-153,227
Closed -$5.09M 3511
2022
Q4
$5.09M Buy
153,227
+46,229
+43% +$1.49M 0.01% 1173
2022
Q3
$3.37M Sell
106,998
-21,217
-17% -$687K 0.01% 1672
2022
Q2
$3.9M Buy
128,215
+100,253
+359% +$2.71M 0.01% 1535
2022
Q1
$726K Buy
+27,962
New +$665K ﹤0.01% 2598
2021
Q1
Sell
-126,430
Closed -$2.36M 2988
2020
Q4
$2.36M Buy
126,430
+37,483
+42% +$700K 0.01% 879
2020
Q3
$1.51M Buy
+88,947
New +$1.73M 0.01% 889
2020
Q2
Sell
-167,361
Closed -$1.41M 2062
2020
Q1
$1.41M Sell
167,361
-324,673
-66% -$2.73M 0.01% 725
2019
Q4
$4.81M Buy
492,034
+104,835
+27% +$984K 0.03% 547
2019
Q3
$3.67M Buy
387,199
+74,313
+24% +$783K 0.03% 589
2019
Q2
$3.72M Buy
312,886
+231,721
+285% +$2.79M 0.03% 581
2019
Q1
$1.43M Sell
81,165
-158,223
-66% -$2.63M 0.01% 835
2018
Q4
$4.16M Buy
+239,388
New +$4.08M 0.04% 506
2016
Q3
Sell
-12,587
Closed -$245K 1184
2016
Q2
$245K Buy
+12,587
New +$247K ﹤0.01% 918
2015
Q3
Sell
-75,021
Closed -$1.4M 1098
2015
Q2
$1.4M Buy
+75,021
New +$1.39M 0.02% 542

Other funds holding VIVO

Marshall Wace's VIVO Position: Q1 2023 in Review

Marshall Wace sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 153,227 shares — an estimated $5.09M sold.

Marshall Wace first reported a position in VIVO in Q2 2015 and held it in 14 quarters. The position peaked at $5.09M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Marshall Wace reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Marshall Wace sold 153,227 Meridian Bioscience Inc shares in Q1 2023, an estimated $5.09M.
  • Marshall Wace first reported a position in Meridian Bioscience Inc in Q2 2015 and held it in 14 quarters.
  • Marshall Wace's Meridian Bioscience Inc position peaked at $5.09M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.